6/19/2026

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Lyxumia

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Lixisenatid

Lixisenatid

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Kettner J, Donnelly E, Maes ML. Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications. J Pharm Pract. 2026 6;39(3):239-250.

  2. Armstrong BBS, Servidoni ACP, Martin GCC, Machado GF, Amador WFO, Yousif A. Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis. J Gynecol Obstet Hum Reprod. 2025 12;54(10)

  3. Dao K, Shechtman S, Weber-Schoendorfer C, Diav-Citrin O, Murad RH, Berlin M, Hazan A, Richardson JL, Eleftheriou G, Rousson V, Diezi L, Haefliger D, Simões-Wüst AP, Addor MC, Baud D, Lamine F, Panchaud A, Buclin T, Girardin FR, Winterfeld U. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. 2024 4;14(4)

  4. Chou YC, Weng SH, Cheng FS, Tseng CH, Hu HY, Liu CH. Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan. Diabetes Obes Metab. 2026 2;28(2):1420-1430.

  5. Cesta CE, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K, Gissler M, Huybrechts KF, Kjerpeseth LJ, Leinonen MK, Pazzagli L, Zoega H, Seely EW, Patorno E, Hernández-Díaz S. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med. 2024 2 1;184(2):144-152.

  6. Parker CH, Slattery C, Brennan DJ, le Roux CW. Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials. Diabetes Obes Metab. 2025 8;27(8):4102-4108.

  7. Brown JP, Huybrechts KF, Straub L, Patorno E, Seely EW, Bateman BT, Hernández-Díaz S. Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes : A Target Trial Emulation Study Using Claims Information. Ann Intern Med. 2026 June 9.

  8. Cesta CE, Hutcheon JA, Johansson K. Guiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist Use. JAMA. 2025 12 23;334(24):2168-2170.

  9. Sanofi AB. Suliqua. Produktresumé. EMA [www]. [updated 2024-10-25, cited 2026-06-01].

  1. Kettner J, Donnelly E, Maes ML. Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications. J Pharm Pract. 2026 6;39(3):239-250.
  2. Armstrong BBS, Servidoni ACP, Martin GCC, Machado GF, Amador WFO, Yousif A. Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis. J Gynecol Obstet Hum Reprod. 2025 12;54(10)
  3. Dao K, Shechtman S, Weber-Schoendorfer C, Diav-Citrin O, Murad RH, Berlin M, Hazan A, Richardson JL, Eleftheriou G, Rousson V, Diezi L, Haefliger D, Simões-Wüst AP, Addor MC, Baud D, Lamine F, Panchaud A, Buclin T, Girardin FR, Winterfeld U. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. 2024 4;14(4)
  4. Chou YC, Weng SH, Cheng FS, Tseng CH, Hu HY, Liu CH. Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan. Diabetes Obes Metab. 2026 2;28(2):1420-1430.
  5. Cesta CE, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K, Gissler M, Huybrechts KF, Kjerpeseth LJ, Leinonen MK, Pazzagli L, Zoega H, Seely EW, Patorno E, Hernández-Díaz S. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med. 2024 2 1;184(2):144-152.
  6. Parker CH, Slattery C, Brennan DJ, le Roux CW. Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials. Diabetes Obes Metab. 2025 8;27(8):4102-4108.
  7. Brown JP, Huybrechts KF, Straub L, Patorno E, Seely EW, Bateman BT, Hernández-Díaz S. Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes : A Target Trial Emulation Study Using Claims Information. Ann Intern Med. 2026 June 9.
  8. Cesta CE, Hutcheon JA, Johansson K. Guiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist Use. JAMA. 2025 12 23;334(24):2168-2170.
  9. Sanofi AB. Suliqua. Produktresumé. EMA [www]. [updated 2024-10-25, cited 2026-06-01].